UP

EMA conditionally approves Pfizer's COVID-19 pill

Home page Health
12 Punto 14 Punto 16 Punto 18 Punto

The European Medicines Agency (EMA) on Thursday conditionally approved the use of U.S. multinational biotechnology firm Pfizer's COVID-19 pill for treating adults at risk of severe illness.

Axar.az informs that the endorsement allows the member states of the European Union (EU) to deploy the drug after the EMA gave guidance for its emergency use late last year.

The EMA said in a statement that its Committee for Medicinal Products for Human Use (CHMP) had "recommended granting a conditional marketing authorization for the oral antiviral medicine Paxlovid for treating COVID-19 in adults who do not require supplemental oxygen and who are at increased risk of the disease becoming severe."

Paxlovid is the first oral antiviral recommended in the EU for treating COVID-19. It consists of two active substances packaged together. One reduces the ability of SARS-CoV-2 to multiply in the body, while the other enables the first substance to remain longer in the body at levels that affect the multiplication of the virus.

The EMA said it had evaluated data from a study involving patients with COVID-19, which showed that treatment with Paxlovid significantly reduced the risk of hospitalization and death among patients with at least one underlying condition.

Date
2022.01.28 / 11:26
Author
Axar.az
See also

Millions at risk as US ends AIDS funding - UNAIDS report

Smart hydrogel developed to heal chronic wounds faster

WHO pushes bold reforms, launching 3 by 35 initiative

Scientists discover new coronavirus

Azerbaijan performs first deceased donor organ transplants

Fifty countries affected by USAID freeze - WHO

Monkeypox case confirmed in Azerbaijan

WHO calls for international support to fund aid in Gaza

30 metapneumovirus cases reported in Kazakhstan

Human metapneumovirus epidemic reported in China

Latest
Xocalı soyqırımı — 1992-ci il Bağla
Bize yazin Bağla
ArxivBağla